Because STAT1 and STAT3 are required for the development of naïve T cells into Th1 and Th17 lymphocyte, pre-clinical studies examined whether simultaneous inhibition of STAT1 and STAT3 with SBT-100 would be effective therapy for multiple sclerosis. This evidence concerns the gene STAT3 and multiple sclerosis.